FDA — authorised 11 October 2024
- Application: BLA761369
- Marketing authorisation holder: PFIZER INC
- Local brand name: HYMPAVZI
- Indication: INJECTABLE — SUBCUTANEOUS
- Status: approved
FDA authorised Hympavzi on 11 October 2024
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 11 October 2024; FDA has authorised it.
PFIZER INC holds the US marketing authorisation.